NRx Pharmaceuticals, HOPE Therapeutics complete Dura Medical acquisition

HOPE Therapeutics announced the closing of the previously announced acquisition of Dura Medical. Dura, together with the pending Neurospa TMS and Cohen and Associates acquisitions, are planned to provide a comprehensive service offering to patients at more than 8 locations along the West Coast of Florida. Dura is revenue generating and EBITDA positive. Dura Medical, with existing locations in Naples and Ft. Myers, Florida, was founded in 2018 to offer a gold-standard, precision approach to treating depression, PTSD, and chronic pain on the West Coast of Florida. More than 13 million Americans contemplate suicide each year and an American dies from suicide every 11 minutes. Dura leverages the latest interventional psychiatry procedures, including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation, Spravato and Stellate Ganglion Blocks, augmented by traditional psychiatry and therapy to provide a full continuum of care for people with depression, suicidality, PTSD, anxiety, and related disorders. In conjunction with the planned acquisition, HOPE is proud to appoint Mr. Durand as Director of Florida Clinic Operations.